{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:58:40Z","timestamp":1793649520484,"version":"4.5.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015682","name":"Fundaci\u00f3n INCLIVA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015682","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013405","name":"Instituto de Investigacion Sanitaria de la Fundacion Jimenez Diaz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013405","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports\u00ae"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ekir.2025.09.027","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T04:23:53Z","timestamp":1759551833000},"page":"6-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["From Evidence to Action: Advancing Timely Implementation of Triple Therapy in Type 2 Diabetes Mellitus and CKD"],"prefix":"10.1016","volume":"11","author":[{"given":"Beatriz","family":"Fernandez-Fernandez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis","family":"Gorriz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Cebrian-Cuenca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"F\u00e1cila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Maria","family":"Fernandez Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel Perez","family":"Maraver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2025.09.027_bib1","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.kint.2025.04.005","article-title":"Preventing chronic kidney disease and maintaining kidney health: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"108","author":"Ortiz","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.09.027_bib2","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.09.027_bib3","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1016\/S0140-6736(24)00685-8","article-title":"Burden of disease scenarios for 204 countries and territories, 2022-2050: a forecasting analysis for the Global Burden of Disease Study 2021","volume":"403","author":"Vollset","year":"2024","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ekir.2025.09.027_bib4","doi-asserted-by":"crossref","first-page":"sfae405","DOI":"10.1093\/ckj\/sfae405","article-title":"The ERA registry annual report 2022: epidemiology of kidney replacement therapy in Europe, with a focus on sex comparisons","volume":"18","author":"Boenink","year":"2024","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2025.09.027_bib5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of Semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"New Eng J Med"},{"key":"10.1016\/j.ekir.2025.09.027_bib6","doi-asserted-by":"crossref","first-page":"S239","DOI":"10.2337\/dc25-S011","article-title":"Chronic kidney disease and risk management: standards of care in diabetes-2025","volume":"48","author":"ElSayed","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ekir.2025.09.027_bib7","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"New Eng J Med"},{"key":"10.1016\/j.ekir.2025.09.027_bib8","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"New Eng J Med"},{"key":"10.1016\/j.ekir.2025.09.027_bib9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/eurjpc\/zwab154","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"29","author":"Visseren","year":"2022","journal-title":"Eur J Prevent Cardiol"},{"key":"10.1016\/j.ekir.2025.09.027_bib10","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"New Eng J Med"},{"key":"10.1016\/j.ekir.2025.09.027_bib11","first-page":"117","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2022","journal-title":"N Eng J Med"},{"key":"10.1016\/j.ekir.2025.09.027_bib12","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Eng J Med"},{"key":"10.1016\/j.ekir.2025.09.027_bib13","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with Finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Eng J Med"},{"key":"10.1016\/j.ekir.2025.09.027_bib14","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: The FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ekir.2025.09.027_bib15","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.2337\/dc22-0294","article-title":"Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: the FIDELITY analysis","volume":"45","author":"Rossing","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ekir.2025.09.027_bib16","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1093\/ckj\/sfad082","article-title":"EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors","volume":"16","author":"Fern\u00e1ndez-Fernandez","year":"2023","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2025.09.027_bib18","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/ckj\/sfac199","article-title":"Chronic kidney disease as cardiovascular risk factor in routine clinical practice: a position statement by the Council of the European Renal Association","volume":"16","author":"Ortiz","year":"2022","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2025.09.027_bib19","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.nefro.2021.07.010","article-title":"Information and consensus document for the detection and management of chronic kidney disease","volume":"42","author":"Garc\u00eda-Maset","year":"2022","journal-title":"Nefrologia"},{"key":"10.1016\/j.ekir.2025.09.027_bib20","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.nefro.2018.04.004","article-title":"Prevalencia de enfermedad renal cr\u00f3nica en Espa\u00f1a: impacto de la acumulaci\u00f3n de factores de riesgo cardiovascular","volume":"38","author":"Gorostidi","year":"2018","journal-title":"Nefrolog\u00eda"},{"key":"10.1016\/j.ekir.2025.09.027_bib21","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.nefro.2023.02.004","article-title":"The Spanish Scientific Societies before the ESC 2021 guidelines on vascular disease prevention: Generalizing the measurement of albuminuria to identify vascular risk and prevent vascular disease","volume":"43","author":"Ortiz","year":"2023","journal-title":"Nefrologia"},{"key":"10.1016\/j.ekir.2025.09.027_bib22","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/ndt\/gfaf057","article-title":"ABCDE to identify and prevent chronic kidney disease: a call to action","volume":"40","author":"Ferro","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2025.09.027_bib23","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.2337\/dc20-2715","article-title":"Chronic kidney disease testing among primary care patients with type 2 diabetes across 24 U.S. health care organizations","volume":"44","author":"Stempniewicz","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ekir.2025.09.027_bib24","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfaf123","article-title":"Impact of albuminuria screening in primary care on the detection and management of chronic kidney disease: findings from the ONDAAS study","volume":"18","author":"S\u00e1nchez-Ospina","year":"2025","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2025.09.027_bib26","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1370\/afm.2338","article-title":"Burnout and health care workforce turnover","volume":"17","author":"Willard-Grace","year":"2019","journal-title":"Ann Fam Med"},{"key":"10.1016\/j.ekir.2025.09.027_bib27","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1007\/s40620-024-02070-y","article-title":"First interim results from FINE-REAL: a prospective, non-interventional, phase 4 study providing insights into the use and safety of finerenone in a routine clinical setting","volume":"37","author":"Nicholas","year":"2024","journal-title":"J Nephrol"},{"key":"10.1016\/j.ekir.2025.09.027_bib28","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/MAJ.0000000000000475","article-title":"Underprescription of renin-angiotensin system blockers in moderate to severe chronic kidney disease","volume":"349","author":"Shirazian","year":"2015","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.ekir.2025.09.027_bib29","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.2215\/CJN.0000000000000550","article-title":"Baseline, early changes, and residual albuminuria: post-hoc analysis of a clinical trial of dapagliflozin in chronic kidney disease","volume":"19","author":"van Mil","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.09.027_bib30","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","article-title":"Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials","volume":"6","author":"Perkovic","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ekir.2025.09.027_bib31","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jacc.2019.11.036","article-title":"Clinical benefit of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review","volume":"75","author":"Zelniker","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ekir.2025.09.027_bib32","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.2215\/CJN.0000000000000526","article-title":"Reframing chronicity with urgency in chronic kidney disease management","volume":"19","author":"Neuen","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.09.027_bib33","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1681\/ASN.0000000752","article-title":"Rapid and simultaneous initiation of guideline-directed kidney therapies in patients with CKD and type 2 diabetes","volume":"36","author":"Rashid","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.09.027_bib35","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S2213-8587(21)00243-6","article-title":"Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Jongs","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ekir.2025.09.027_bib36","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1038\/s41591-024-03133-0","article-title":"Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial","volume":"30","author":"Mann","year":"2024","journal-title":"Nature Med"},{"key":"10.1016\/j.ekir.2025.09.027_bib37","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S2213-8587(17)30182-1","article-title":"Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial","volume":"5","author":"Cherney","year":"2017","journal-title":"Lancent Diabetes Endocrinol"},{"key":"10.1016\/j.ekir.2025.09.027_bib38","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/sj.ijo.0803009","article-title":"Effect of weight loss using formula diet on renal function in obese patients with diabetic nephropathy","volume":"29","author":"Saiki","year":"2005","journal-title":"Int J Obes"},{"key":"10.1016\/j.ekir.2025.09.027_bib39","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1681\/ASN.2014070688","article-title":"Drug-induced reduction in albuminuria is associated with subsequent renoprotection: a meta-analysis","volume":"26","author":"Heerspink","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.09.027_bib40","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/ndt\/gfac198","article-title":"Design of the combination effect of finerenone and empagliflozin in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE)","volume":"38","author":"Green","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2025.09.027_bib41","first-page":"518","article-title":"Combination effect of finerenone and empagliflozin in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: Baseline clinical characteristics","volume":"16","author":"Agarwal","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2025.09.027_bib42","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes","volume":"393","author":"Agarwal","year":"2025","journal-title":"N Eng J Med"},{"key":"10.1016\/j.ekir.2025.09.027_bib43","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.7326\/M23-1023","article-title":"Impact of Finerenone-induced albuminuria reduction on chronic kidney disease outcomes in type 2 diabetes","volume":"176","author":"Agarwal","year":"2023","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ekir.2025.09.027_bib44","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/ndt\/gfab167","article-title":"Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease","volume":"38","author":"Ortiz","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2025.09.027_bib45","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/ckj\/sfae296","article-title":"GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity","volume":"17","author":"Abasheva","year":"2024","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2025.09.027_bib46","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/ckj\/sfac274","article-title":"Tirzepatide and prevention of chronic kidney disease","volume":"16","author":"Bosch","year":"2022","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2025.09.027_bib47","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1053\/j.ajkd.2025.03.001","article-title":"GLP-1 receptor agonists for CKD: remaining issues or mission complete?","volume":"85","author":"Kosjerina","year":"2025","journal-title":"Am J Kidney Dis"}],"container-title":["Kidney International Reports\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024925006011?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024925006011?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T19:26:57Z","timestamp":1773257217000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024925006011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2468024925006011"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2025.09.027","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From Evidence to Action: Advancing Timely Implementation of Triple Therapy in Type 2 Diabetes Mellitus and CKD","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports\u00ae","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2025.09.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}